Treating plaque, not data!!作者認為治療LDL不如量測carotid plaque

Treating Disease, Not Risk Factors

Observational data suggest that using total carotid arterial plaque burden to guide therapy can improve markers of atherosclerotic disease.

Quantitative measures of atherosclerosis, such as carotid intima–media thickness, are considered to be strong surrogate markers of disease progression. However, patients with hyperlipidemia are typically treated to target LDL and HDL levels, without regard to quantitative measures of plaque. In 2001, investigators at a vascular prevention clinic in western Ontario, Canada, began using the results of ultrasound measurement of total carotid plaque area, rather than lipid levels, to guide treatment in adults with known atherosclerotic disease. They compared their plaque-progression results through 2007 with those of the 5-year period before 2001, during which target lipid levels were used to guide treatment.

The investigators included serial plaque measurements from 4378 patients (47% women). Mean age at referral was 60 overall; during 1997–2001, mean age increased from 50 to 61 as the proportion of patients referred after a stroke grew. In 2001–2002, plaque was progressing in 55% of patients and regressing in 26%. By 2006, these proportions had essentially reversed: Plaque was regressing in 50% and progressing in 27%. In earlier years, patients with plaque progression had higher levels of LDL than those with regression. However, by 2007, LDL levels in patients with progression were approximately half as high as in earlier years and were actually lower than LDL levels in patients with regression.

Comment: The rationale for this treatment paradigm is that, as the authors put it, "treating arteries without measuring plaque would be like treating hypertension without measuring blood pressure." In this single-center study, treatment based on carotid total plaque area led to a substantial increase in plaque regression as compared with treatment based on lipid levels. However, these results must be tested in a large randomized trial with hard clinical outcomes before a major shift in clinical practice can be recommended.

留言

張貼留言

這個網誌中的熱門文章

即便是用IGRA, 有時也要等大於三個月才能決定TB contact

圖片
接觸TB後，TST大抵上2-12週轉陽，IGRA大抵上6-10週，但IGRA可以長到3個月以上 TB Tests Can Have a Lengthy Window Period Two studies suggest that interferon- release assay conversion sometimes occurs more than 3 months after exposure to active tuberculosis. Increasingly, interferon- release assays (IGRAs) are being used for diagnosing latent tuberculosis (TB). Although the tuberculin skin test (TST) traditionally used for this purpose converts to positive within 2 to 12 weeks after an individual is exposed to someone with active TB, the interval for IGRA conversion has remained unclear. Current guidelines recommend repeating an initially negative IGRA after 6 to 10 weeks, but this recommendation is not based on controlled studies. Two recent investigations address this issue. Anibarro and colleagues conducted a longitudinal prospective analysis among contacts of TB patients in Spain. The 152 contacts received a TST and an IGRA at first visit; for individuals with negative or conflicting results, t
閱讀完整內容

白宮為了掌控醫療費用，傾向大型醫療，個體戶勢必受挫

所以一旦政府介入，中外醫療提供者都傾向大型化…… independent practice -> dreaming 診所評鑑??應該擋住! http://www.medscape.com/viewarticle/727420 Physicians Say White House Should Not Write Off Small Practices August 24, 2010 — In a newly published article, the White House is advising physicians to accept a life in Big Medicine — as a hospital employee or member of a large group practice — in the wake of healthcare reform. Some leaders of organized medicine, however, are objecting to the government message. "We're not ready to write off the small practices," J. Fred Ralston Jr, MD, president of the American College of Physicians, told Medscape Medical News. "We think there needs to be more than one delivery model." "America is not a one-size-fits-all country," added M. Todd Williamson, MD, a neurologist from Lawrenceville, Georgia, and spokesperson for a coalition of medical societies opposed to the new healthcare reform law, now called the Affordable Care Act. Dr. Ralston and Dr.
閱讀完整內容

老美接受LTBI treatment的人，不到一半完治，和duration成正比

This study shows that although acceptance of LTBI treatment is relatively high (83%), the proportion completing is low (47%). When the product of these two proportions is calculated, we see that completion was achieved by only 39% of persons who were offered LTBI treatment. The major risk factor for noncompletion was being prescribed the 9-month INH regimen. As shown in Figure 1, when the proportions completing the three most commonly prescribed regimens are compared, it can be seen that there is an inverse relationship between length of the regimen prescribed and the proportion completing treatment. The increased completion that we observed with the 4-month rifampin regimen is consistent with previous reports.[18–20] It is of interest to note that if completion of the 9-month regimen were defined as completion of at least 6 months of INH, the noncompletion rate of the 9-month regimen, 42.9%, would have been almost identical to that of the 6-month regimen, 44.8%. Thus, prescribing the
閱讀完整內容